Skip to main content
Download PDF

Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging

Journal of Translational Medicine volume 21, Article number: 636 (2023) Cite this article

The Original Article was published on 07 June 2023


Correction: Journal of Translational Medicine (2023) 21:367  https://doi.org/10.1186/s12967-023-04142-2


Following publication of the original article [1], we have been notified that the legend order of X axis in Fig. 7 was incorrect. The corrected x-axis legend Fig. 7 is given below:

Fig. 7
figure 7

89Zr-oxine radiolabeling did not interfere with the biological functional potency of CAR-T cells. A In vitro potency assay of radiolabeled and unlabeled CAR-T cells showed no significant difference in their IL-13Rα2 positive target tumor cell killing abilities in a co-culture assay as described in Materials and Methods. B Co-culture assay of labeled and unlabeled CAR-T effector cells with IL-13Rα2 positive U251, A172 and U87MG target cells showed similar values of IFN-γ release in 20-h culture. IL-13Rα2 negative T98G glioma cells co-cultured with labeled and unlabeled CAR-T cells secreted basal amounts of IFN-γ. A representative data of three independent experiments performed in quadruplicate is shown

Full size image

Reference

  1. Leland P, Kumar D, Nimmagadda S, Bauer SR, Puri RK, Joshi BH. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging. J Transl Med. 2023;21:367. https://doi.org/10.1186/s12967-023-04142-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Steven R. Bauer

    Present address: Wake Forest Institute of Regenerative Medicine, Winston Salem, NC, USA

  2. Raj K. Puri

    Present address: Iovance Biotherapeutics, San Carlos, CA, USA

  3. Deceased—Pamela Leland.

Authors and Affiliations

  1. Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advance Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA

    Pamela Leland, Steven R. Bauer, Raj K. Puri & Bharat H. Joshi

  2. Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Dhiraj Kumar & Sridhar Nimmagadda

Authors
  1. Pamela Leland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dhiraj Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sridhar Nimmagadda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven R. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raj K. Puri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bharat H. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bharat H. Joshi.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s12967-023-04142-2.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leland, P., Kumar, D., Nimmagadda, S. et al. Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging. J Transl Med 21, 636 (2023). https://doi.org/10.1186/s12967-023-04496-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12967-023-04496-7

Journal of Translational Medicine

ISSN: 1479-5876

Contact us